FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “INOVIO Announced that the U.S. Govt has Stopped Funding for its Late-Stage Covid-19 Vaccine Study”
INOVIO (NASDAQ: INO) shares dropped over 27% after the company announced that various government bodies will discontinue funding for the Phase 3 segment of the INNOVATE trial, while continuing to fund the completion of the ongoing Phase 2 segment
As such, INOVIO will now adjust its INO-4800 clinical development strategy to focus on global unmet COVID-19 vaccine needs, and is planning for a predominantly ex-US global Phase 3 trial based on upcoming evaluation of Phase 2 safety and immunogenicity data.
INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response.
For more information, please visit: Inovio Pharmaceuticals, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.